▎WuXi AppTec Content Team Report

On December 12, iRegene announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration officially approved the IND application for the company's pipeline candidate NouvNeu003.This pipeline targets early-onset Parkinson's disease, addressing Parkinson's patients with an age of onset under 50.According to iRegenePharmaceuticalsThis is the second IND approval for iRegene this year, following the approval in August for the Phase 1-2 combined clinical trial of the Parkinson's disease drug NouvNeu001.In terms of indications, NouvNeu003 and NouvNeu001 target the two major patient populations of Parkinson's disease—"one elderly and one early-stage"—while encompassing both genetic and non-genetic types., realizing iRegene's strategic layout for full lifecycle and full treatment cycle coverage in the Parkinson's field.

Screenshot source:CDE Official Website

Parkinson's disease can also occur in young people. According to statistics, the youngest age of onset for Parkinson's is only 7 years old. Onset before the age of 50 is referred to as Early-Onset Parkinson's Disease (EOPD), which has been included in China's First List of Rare Diseases.

iRegene focuses on researching the regeneration of functional cells induced by highly efficient chemical small molecules. Since its establishment, the company has aimed to reverse the progression of neurodegenerative diseases such as Parkinson's through the regulation and transformation of cell fate.NouvNeu001 is aChemical-Induced Universal Cell Therapy Products, which achieves high-purity neuronal subtype reconstruction and functional optimization through compound regulation, forms connections with the original neurons in the body, and enhances cellular secretion functions, further strengthening the improvement of the original lesion by the transplanted cells to achieve a comprehensive therapeutic effect.。As for NouvNeu003, itEarly-Onset Parkinson's DiseaseFor the indication, targeting Parkinson's patients with onset age under 50.

According to the news release from iRegene, there is a strong synergy between the NouvNeu003 and NouvNeu001 pipelines, with potential for collaborative insights in areas ranging from pathogenesis to clinical treatment plans.Moreover, since early-stage Parkinson's is even rarer, NouvNeu003 is also expected to become an "orphan drug."This makes its clinical progress and market launch potentially faster, benefiting patients earlier.In this process, NouvNeu003 can also provide empirical guidance for the clinical work of NouvNeu001, helping it reach the market more quickly.

iRegeneUnitedFounder and Chief Executive Officer (CEO)Dr. Wei JunIntroduced in an earlier interview with the WuXi AppTec content team: "Adhering to 'Starting from the needs of patients, solve realPositive Clinical DemandThe purpose of iRegene is to prioritize safety and accessibility, innovate from the source, and ultimately form a unique’AI + Chemical InductionSystemSpecifically, we first utilize knowledge graphs for enrichment analysis of core genes in developmental biology; then, by integrating omics analysis and calculating the topological structure of interaction networks, we anchor specific key developmental pathways and their inducing compounds, thereby determining the most suitable cell and chemical induction development processes for treatment. Ultimately,Only a small number of appropriate chemical small molecules combined with basic culture medium can achieve efficient and precise conversion of pluripotent stem cells into target cells on an industrial scale.This concept also helps the company's research products achieve faster and better therapeutic effects."

References: